Marengo Therapeutics’ Post

"We believe STAR0602 could be game-changing for patients who fail to respond to checkpoint inhibitors, because it promotes antitumor activity via a very different mechanism, characterized by expansion of a new subset of memory Vβ T cells that reinvigorate the T cell response to tumors." ICYMI: As a follow up to the paper published in Science Translational Medicine, Marengo's CSO Andrew Bayliffe spoke with the team at ACIR.

Please welcome Srinjoy Chakraborti, PhD, who joined Marengo earlier this July. We are ecstatic to have you with us!   Check out our current open roles: https://lnkd.in/eQCzHw7z

Earlier this month, Marengo’s research team embarked on a helpful offsite team-building event, graciously hosted by Claria Partners . During this event, we delved into our Insights Discovery results. The Insights Discovery tool uses a 4-color model to help people understand their style, their strengths, and the value they bring to the team.   As the final group at Marengo to undergo this process, our scientists were eager to uncover their results and compare them with those of their colleagues. It came as no surprise that "cool blue" emerged prominently among our team.   Our heartfelt thanks to Claria Partners for orchestrating such a valuable and insightful event. Many of our team members continue to reflect on the profound insights gained.

This summer, we’ve been extremely fortunate to have Keana Ramos Baptista on our team. Keana, who is about to enter her junior year at Boston University, has spent the past few months assisting the Marengo team in the office and the lab. Her contributions have made her an invaluable member of our People & Culture team. We met Keana through Project Onramp , a wonderful program by Life Science Cares Boston. We are truly grateful for the dedication and enthusiasm she has brought to her internship. We are excited to see all the amazing things Keana will accomplish in the future and wish her the very best. Learn more about the program here: https://projectonramp.us

Attending DIA (Drug Information Association)'s Global Annual Meeting in San Diego? Join Marengo's Chief Development Officer Ke Liu , MD, PhD for their panel session to interpret FDA guidance, discuss trends, and share their own experiences for study design in cell and gene therapy trials.

🌟 Nasdaq celebrates the extension of the strategic partnership between Marengo Therapeutics and Ipsen! This collaboration continues to drive innovation and growth in the biotech sector for better treatment for patients, setting new standards for success. 🚀 A special thanks to the Nasdaq team for this honor! ATP (Apple Tree Partners) #Nasdaq #Marengo #Ipsen #Biotech #Partnership #oncology

Exciting News! Today Marengo Therapeutics jointly announced our expanded partnership with Ipsen to advance precision T cell engagers from our Tri-STAR platform, targeting difficult-to-treat ‘cold’ tumors. Marengo is eligible to receive up to $1.2 billion plus tiered royalties to progress our mission: The right activation of the right immune cells to promote lifelong protection against cancer Learn more: https://lnkd.in/e4h9-kqu #Biotech #immunooncology #Partnership #Innovation #CancerResearch #Oncology #MarengoTherapeutics #Ipsen